

Bromofluorination of Vinyloxiranes

Ahmed Hedhli and Ahmed Baklouti*

Laboratoire de Chimie Structurale Organique, Département de Chimie, Faculté des Sciences de Tunis, Campus Universitaire, 1060 Tunis, Tunisia

Received March 10, 1994[®]


The action of *N*-bromosuccinimide/triethylamine tris(hydrofluoride) (NBS/Et₃N·3HF) on vinyloxiranes leads to the corresponding bromofluorinated oxiranes. The regioselectivity and yield of the reaction can be related to the degree of substitution on the vinyl group.

Introduction

The halofluorinating reagent XF (X = Cl, Br, I) is generally generated in situ from fluorine and bromine,¹⁻³ from silver fluoride and halogen,⁴ or by combination of a positive halogen precursor, such as alkyl hypochlorite, *N*-halosuccinimide or *N*-bromoacetamide, with HF,⁵⁻⁷ HF/pyridine,⁸⁻¹⁰ or Bu₄NH₂F₃.^{11,12} The XF addition using the mixture NBS/Et₃N·3HF has been realized on simple olefins^{13,14} and allylic alcohols.¹⁵ In the present work this reaction is carried out on the vinyloxiranes and yields the corresponding bromofluoro oxiranes. The formation of these simple building-block molecules may prove useful in syntheses of fluorine-substituted products.

Results and Discussion

At room temperature, the action of triethylamine tris(hydrofluoride) on the vinyloxiranes leads, via oxirane ring opening, to the corresponding fluorohydrins¹⁶ whereas the mixture NBS/Et₃N·3HF yields from the same vinyloxiranes, at -10 °C in dichloromethane, the corresponding bromofluoro oxiranes, as shown below.



The synthesised products are shown in Table 1.

The results shown in Table 1 allow us to make the following comments: (i) The regioselectivity of the reaction, partial when the vinyl group of the starting vinyloxiranes is not substituted, becomes total for vinylox-

- [®] Abstract published in *Advance ACS Abstracts*, August 1, 1994.
 (1) Brand, M.; Rozen, S. *J. Fluorine Chem.* **1982**, *20*, 419.
 (2) Rozen, S.; Brand, M. *J. Org. Chem.* **1985**, *50*, 3342.
 (3) Rozen, S.; Brand, M.; Lidor, R. *J. Org. Chem.* **1988**, *53*, 5545.
 (4) (a) Hall, L. D.; Jones, D. L.; Manville, J. F. *Chem. Ind.* **1976**, 1787. (b) Hall, L. D.; Manville, J. F. *Chem. Commun.* **1968**, 35. (c) Hall, L. D.; Jones, D. L. *Can. J. Chem.* **1973**, *51*, 2902.
 (5) Wittig, G.; Mayer, U. *Chem. Ber.* **1963**, *96*, 329.
 (6) Pattison, F. L. M.; Peters, D. A. V.; Dean, F. H. *Can. J. Chem.* **1965**, *43*, 1689.
 (7) Dean, F. H.; Pattison, F. L. M. *Can. J. Chem.* **1965**, *43*, 2415.
 (8) Olah, G. A.; Nojima, M.; Kerekes, I. *Synthesis* **1973**, 780.
 (9) Zupan, M. *J. Fluorine Chem.* **1977**, *9*, 177.
 (10) Chi, D. Y.; Kiesewetter, D. O.; Katzenellenbogen, J. A. *J. Fluorine Chem.* **1986**, *31*, 99.
 (11) Kuroboshi, M.; Hiyama, T. *Tetrahedron Lett.* **1991**, *32*, 1215.
 (12) Albanese, D.; Landini, D.; Penso, M.; Pratelli, M. *Gazz. Chim. Ital.* **1991**, *121*, 537.
 (13) Haufe, G.; Alvernhe, G.; Laurent, A. *Tetrahedron Lett.* **1986**, *27*, 4449.
 (14) Alvernhe, G.; Laurent, A.; Haufe, G. *Synthesis* **1987**, 562.
 (15) Chehidi, I.; Chaabouni, M. M.; Baklouti, A. *Tetrahedron Lett.* **1989**, *30*, 3167.
 (16) Hedhli, A.; Baklouti, A. *J. Fluorine Chem.*, in press.


Table 1. Preparation of Bromofluoroepoxides

Vinyloxirane	Product	R.C (%) ^a	D1 : D2 ^b	bp (°C/Torr)	Yield (%) ^c
		73	49:51 ^d	70/15	55
		27	58:42 ^d		
		61	29:71 ^d	72/15	66
		39	55:45 ^d		
		-	31:69 ^d	81/15	79
		-	79:21	98/0.3	93
		-	77:23	73/15	67

^a R.C.: regioisomer composition based on ¹⁹F NMR and GC. ^b D1: D2: diastereoisomer composition based on ¹⁹F NMR. ^c Isolated yield. ^d D1 = *erythro*, D2 = *threo* based on ¹⁹F NMR.

iranes, where this group is substituted. (2) The formation of only two diastereoisomers D1 and D2 from each of compounds **4** and **5** excludes the existence of a bromonium ring ⇌ β-brominated carbocation equilibrium for which four diastereoisomers are expected for each of the derivatives and the bromofluorinated oxirane, with benzylic fluorine atom, must be present from compound **4**.

As shown below, the results may be rationalized with an unsymmetrical bromonium ring intermediate. The action of fluoride ion on this ring takes place preferably on the C2 carbon for compounds **1** and **2** and exclusively on this carbon for the other products.



Notice that, contrary to what has been observed in the case of compound **4** (R₁ = Ph), styrene derivative bro-

mofluorination yields the corresponding bromofluorinated compounds with the fluorine atom at the benzylic position.^{17,18}

Experimental Section

¹H NMR spectra were recorded in CDCl₃ on a JEOL NM-PMX apparatus at 60 MHz, and ¹⁹F NMR spectra were obtained in CDCl₃ on a Bruker AC200 instrument at 188.313 MHz. The chemical shifts are reported in ppm relative to TMS and CFC1₃ used as internal standards for the ¹H and ¹⁹F, respectively. IR spectra were carried out on a Perkin-Elmer 681 spectrophotometer. GC analyses were performed on an Intersmat IGC 120 DFL gas chromatograph with a SE 30 (10%) column. Mass spectral (MS) data were obtained on a Nermag R 10-10-B mass spectrometer operating at 70 eV in the impact mode.

Preparation of Bromofluorinated Oxiranes: General Procedure. A 100-mL three-necked round-bottomed flask equipped with a mechanical stirrer, pressure equalizing addition funnel, and nitrogen inlet was charged with 10 mmol of vinylloxirane and 20 mL of dry CH₂Cl₂. The flask was cooled to -10 °C. N-bromosuccinimide (1.78 g, 10 mmol) was added. The reaction mixture was stirred while Et₃N·3HF (3.22 g, 20 mmol) dissolved in CH₂Cl₂ (6 mL) was added dropwise. Stirring was kept overnight at -10 °C. The mixture was then diluted with water and extracted with ether. The organic layer was washed with sodium bicarbonate until basic pH and then with water. After the organic layer was dried on Na₂SO₄, the solvents were removed and the residue obtained was distilled.

1c: IR (CHCl₃) 3000, 1095, 860 cm⁻¹; ¹H NMR δ 4.60 (dm, 1 H, *J* = 47.1 Hz), 3.58 (dd, 2 H, *J* = 20.8, 5.0 Hz), 3.26 (dm, 1 H, *J* = 9.8 Hz), 2.83 (m, 2 H); ¹⁹F NMR δ *erythro* -189.5 (dtd, 1 F, *J* = 47.1, 20.8, 9.8 Hz), *threo* -184.5 (dtdd, 1 F, *J* = 47.0, 16.8, 13.4, 4.0 Hz); MS (*m/z*) 138/140 (M - CH₂O, 1.79/1.40), 93/95 (CH₂Br, 6.33/5.71), 89 (M - Br, 19.21), 60 (16.44), 51 (60.10), 41 (100.00).

1c': IR (CHCl₃) 3000, 1095, 860 cm⁻¹; ¹H NMR δ 4.70 (dd, 2 H, *J* = 47.0, 18.3 Hz), 4.26 (m, 1 H), 3.26 (m, 1 H), 2.83 (m, 2 H); ¹⁹F NMR δ *erythro* -217.3 (td, 1 F, *J* = 47.0, 18.3 Hz), *threo* -210.3 (td, 1 F, *J* = 47.2, 14.0 Hz); MS (*m/z*) 89 (M - Br, 18.36), 60 (13.46), 51 (75.86), 41 (100.00).

2c: IR (CHCl₃) 2990, 1090, 865 cm⁻¹; ¹H NMR δ 4.57 (dm, 1 H, *J* = 49.0 Hz), 3.59 (dm, 2 H, *J* = 25.3 Hz), 3.05 (m, 2 H), 1.38 (s, 3 H, *threo*), 1.23 (s, 3 H, *erythro*); ¹⁹F NMR δ *erythro* -198.3 (dt, 1 F, *J* = 49.0, 25.4 Hz), *threo* -194.2 (dt, 1 F, *J* = 49.4, 21.2 Hz); MS (*m/z*) 102 (M - HBr, 1.03), 93/95 (CH₂Br, 3.53/2.61), 69 (2.38), 55 (100.00).

2c': IR (CHCl₃) 2990, 1090, 865 cm⁻¹; ¹H NMR δ 4.73 (dm, 2 H, *J* = 49.5 Hz), 4.05 (dm, 1 H, *J* = 14.1 Hz), 3.05 (m, 2 H), 1.60 (s, 3 H, *threo*), 1.48 (s, 3 H, *erythro*); ¹⁹F NMR δ *erythro* -223.4 (td, 1 F, *J* = 49.0, 14.1 Hz), *threo* -217.5 (td, 1 F, *J* = 49.0, 15.0 Hz); MS (*m/z*) 103 (M - Br, 4.89), 84 (7.14), 69 (3.28), 55 (100.00).

3c: IR (CHCl₃) 3000, 1090, 855 cm⁻¹; ¹H NMR δ 3.58 (m, 2 H), 2.65-3.08 (m, 2 H), 1.56 (d, 3 H, *erythro*, *J* = 19.0 Hz), 1.47 (d, 3 H, *threo*, *J* = 22.1 Hz), 1.40 (s, 3 H); ¹⁹F NMR δ *erythro* -159.6 (qt, 1 F, *J* = 21.3, 20.0 Hz), *threo* -154.3 (qdd, 1 F, *J* = 21.9, 21.8, 11.4 Hz); MS (*m/z*) 196 (M⁺, 0.1), 181/183 (M - CH₃, 1.95/1.77), 117 (M - Br, 100.00), 103 (8.92), 93/95 (6.69/6.16), 87 (19.66), 57 (39.20).

4c: IR (CDCl₃) 2980, 1670, 1100, 865 cm⁻¹; ¹H NMR δ 7.30 (s, 5 H), 4.70 (dm, 1 H, *J* = 50.0 Hz), 4.26 (dm, 1 H, *J* = 25.0 Hz), 3.25-3.00 (m, 3 H); ¹⁹F NMR D1 -182.0 (ddd, 1 F, *J* = 50.0, 25.0, 13.6 Hz), D2 -170.7 (ddd, 1 F, *J* = 49.6, 24.4, 15.0 Hz); MS (*m/z*) 244/246 (M⁺, 14.03/13.46), 165 (M - Br, 58.67), 164 (M - HBr, 43.21), 145 (29.58), 105 (100.00), 77 (44.35).

5c: IR (CHCl₃) 2990, 1090, 860 cm⁻¹; ¹H NMR δ 4.90 (dm, 1 H, *J* = 48.0 Hz), 4.21 (dm, 1 H, *J* = 27.5 Hz), 3.80-3.20 (m, 3 H), 1.71 (d, 3 H, D2, *J* = 6.6 Hz), 1.35 (d, 3 H, D1, *J* = 5.8 Hz); ¹⁹F NMR δ D1 -179.9 (ddd, 1 F, *J* = 48.1, 27.4, 24.4 Hz), D2 -169.0 (ddd, 1 F, *J* = 48.0, 24.6, 23.1 Hz); MS (*m/z*) 182/184 (M⁺, 0.61/0.58), 181/183 (M - 1, 0.85/1.25), 167/169 (M - CH₃, 5.39/4.30), 107/109 (CH₃ - CHBr⁺, 0.64/0.73), 103 (M - Br, 17.61), 59 (C₃H₄F⁺, 56.92), 53 (C₄H₅⁺, 100.00).

(17) Gregorcic, A.; Zupan, M. *J. Fluorine Chem.* **1984**, *24*, 291.

(18) Olah, G. A.; Li, X. Y.; Wnag, Q.; Prakash, G. K. S. *Synthesis* **1993**, 693.